Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CowTown Jay is probably paid cheerleader like they always have in penny stocks or some delusional retail investor. the supposedly 30 investors who filed the shareholder lawsuit who was suppose to get .047/share is not posting in social media like yahoo, investorshub or any stock forum, it's because they are fake lawsuits and fake losses.
it doesn't matter of the Lenzilumab ip asset is worth $1 billion and can generate $1 bilion in sales/year
Taran bought the asset which has 'potential' to be worth $4 billion.
Taran owns the patent that it bought for free.
as for milestone payments maximum payment is only $10 million. after legal fees etc you lucky to get $5 million which at best value your hgenq shareholders in the trust get like 5 cents/share.
now if the LENZI drug can have $1 billion per year in sales and is FDA approved. Ask, why did Taran get it for 'free'?
"Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Aug 07, 2023...
Planned interim assessment expected in 2024 following treatment of first 20 participants"
https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-Allogeneic-Stem-Cell-Transplantation/default.aspx
"PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia
Download PDF Copy
These results suggest lenzilumab may normalize hematologic and inflammatory aberrations in CMML and improve the condition of participants."
https://www.news-medical.net/news/20230609/PREACH-M-trial-Lenzilumab-may-improve-treatment-response-in-chronic-myelomonocytic-leukemia.aspx
"Sanofi vaccine deal kicks off Novavax's 'new chapter': Analyst"
https://finance.yahoo.com/video/sanofi-vaccine-deal-kicks-off-202634176.html
Sanofi also announced their "Play to Win" strategy, which includes, "...Investing in over 25 value-creating business development and M&A deals to further strengthen Sanofi’s pipeline."
https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148
see pg 40/85
2. Milestone Payments
The Purchaser, the Foreign Subsidiary, and any other entity that is an Affiliate of the
Purchaser or Foreign Subsidiary that acquires any of the Acquired Assets (the “Regulatory
Milestone Parties” which Regulatory Milestone Party shall include any entity that merges with or
enters into a joint venture with any of the Regulatory Milestone Parties), may be obligated to pay
to the Debtor or its successor or assignee (including, but not limited to, statutory trustees, plan
trustees, plan administrators, litigation trustees, and liquidating trustees) certain contingent
payments (the “Milestone Payments”) in consideration for the Acquired Assets upon achievement
of certain development and commercial milestone events set forth in more detail in section 2.5 of
the APA (as amended by the Third Amendment to Asset Purchase Agreement [Docket No. 140]
and the Fourth Amendment to Asset Purchase Agreement [Docket No. 153] (the “Fourth
Amendment to the APA”)) and summarized below:
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1089767&projectCode=HUM&docketNumber=309&source=DM
chapter 7 is much faster and usually no bankruptcy court is needed. bailliff just seize all assets and liquidate. and distribute to creditors. and shut down operation. especially if the debts are owed to some bank, for this company the debts are owed to vendors as accounts /receivables, normally they never get their money back for accounts receivable account unpaid, owners just bail and leave town.
many business go bankrupt from unpaid accounts receivables and you get collapse. dominoes effect. one large bankruptcy bankrupts 10 other companies etc.
difference between chapter 11 and chapter 7
chapter 11: company still 'exist' and business,employees,customers still operating after completion of chapter 11 and new owners. company operations like bank acounts, credit cards,and employees are not laid off, are not shut down
chapter 7: all assets liquidated, corporation dissolved. shut down. cease to exist. all employees corporation is dissolved and no longer exist.
that reminds me jay can you change the name of the board to taran? or do we have to start a new board , whatever happens we need to follow mr cameron durrant’s
future escapades.
The post you quoted was correct, though not released today but instead on the 19th.
For those wondering why this was not converted to Chapter 7, it's clear from reading the approved docket this is solely due to costs of doing so, and that it would delay payments to secured claims. The purpose of the liquidating trustee in this case is there merely for winding down the business and payments to the aforementioned secured claims.
As for the milestone payments achieved, if any, they will mean nothing to us as members of Class 5.
its great humanigen has all this potential, however it no longer has anything to do with the fact that durrant and his buddies now completely own everything of value.
you dont understand this jay?
it was a devastating blow but i moved on a while ago . and that is correct as of approval of the bankruptcy plan we shareholders got nothing.
and no word from durrant.
im sure he is looking for new money right now and he no longer has to worry about the people he screwed over
How about the complete liquidation of the shares? What is your take? Info was released today.
What allowed Gracell to process CAR-T completion in 24 hours, instead of taking 6 weeks?
Why did the EMA want Novavax to prove their new covid vaccine could show the same results over time, and across a wider area?
In terms of the PREACH-M and RATinG studies, we know that CMML and aGvHD patients may finally have a cure.
Sorry to deduce that lenz may have improved the CAR-T and non-mRNA covid vaccine efficacies, based on speculation, without as much evidence as we see for CMML and aGvHD. I have noted the co-exclusive licensing deal announced between Sanofi and Novavax, for what that might be worth to you, ahead of evidence that lenz is the common denominator, and the licensed product.
There is probably nobody that is more eager for good news than I am, nor more disappointed when potential announcement dates come and go without news.
If people have no clue about what is happening, if they have no appreciation of what lenzilumab's success could mean to them as investors, and they would prefer to be left to wonder, then they should stop reading my posts. Or not. Because as time goes on, I see only MORE reason to be wildly optimistic, as I am. That should come as, "... no news."
I do have to agree with you on this. What does any of this have to do with HGEN?
At this point I only care about HGEN and what is to become of our shares?
Per TwongStocks on ST: Liquidation Plan has been confirmed by the Court, docket 309. https://stkt.co/VDkPePnr
Per the Liquidation Plan, all equity interests (shares) will be cancelled. They do not expect any monetary distribution to shareholders.
My best to all of you who have hung in there through all of this. I am sickened every time I think of this investment. If you are like me and will have nearly an impossible time making up for your losses, I feel for you.
Again great for them. What does this have to do with hgen? No speculation, what does this have to do with hgen? The 13th has come and give add well as the 18th which someone said the meeting had moved to... no news
The Sanofi/Novavax co-exclusive licensing agreement, coupled with the impending spin-off of Sanofi's healthcare sector, coupled yet again with the resignation of Novavax's R&D President, lead me to compare our evolving structural changes to those exhibited by InhibRx.
"Inhibrx Announces Sale of INBRX-101 to
Sanofi for $1.7 Billion Upfront
44
SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY)
("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania
corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1
antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency
("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109,
Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded
company, Inhibrx Biosciences, Inc. ("New Inhibrx").
Under the terms of the agreement, Sanofi will acquire all outstanding shares of Inhibrx through a merger, and in turn, each Inhibrx
shareholder will receive: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent
payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx
per every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Sanofi will assume and retire Inhibrx's
outstanding third party debt and cause New Inhibrx to be funded with $200 million in cash and will retain an equity interest in New Inhibrx
of 8%. The boards of directors of both Inhibrx and Sanofi have unanimously approved the transaction.
Combined, the upfront cash portion of the consideration, the potential contingent value payment, if achieved, and the assumption of
Inhibrx's debt, implies an aggregate transaction value of approximately $2.2 billion. Additionally, Inhibrx shareholders will own 92% of New
Inhibrx capitalized with $200 million in cash."
see pg 44/97
https://www.stifel.com/Newsletters/InvestmentBanking/BAL/Marketing/Healthcare/Biopharma_TimOpler/BiopharmaMarketUpdate_01.29.2024.pdf
Also note the follow-on story on pg 45/97
"Not Your Typical M&A Take-Out: InhibRx Accepts Low Premium in
Exchange for Right to Continue"
Related SEC filing:
https://www.sec.gov/Archives/edgar/data/1121404/000114036124028380/ef20030320_sc13g.htm
I'm just looking for pathways to our success. Not being sure of the pathway is to be expected. But being sure of our success, to me, is also to be expected.
I was wondering when John Hohneker would show up again.
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
May 16, 2024
https://ir.arrivent.com/news-releases/news-release-details/arrivent-appoints-john-hohneker-md-its-board-directors
Cheryl Buxton appears to serve as an Independent Director for Wallmine investment advisors.
https://wallmine.com/otc/hgen/officer/2051278/cheryl-buxton
And we know Kevin Xie's Gracell is now a subsidiary of AstraZeneca, and likely a lenzilumab licensee. I always thought there was an opportunity for us to improve the safety and efficacy of AZ's covid vaccine, in addition to their acquired CAR-T.
https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html
thats a fair point, the only difference is cytodyn has such a huge retail sheep detail following the company that paulson is able to dump shares to at will. no such thing here
That's nothing, could've done an offering with Paulsen Investments like Cytodyn does, they raise $10's of millions they have close to a billion shares. Company had options, question is why didn't they try. They tried for a partnership, didn't work out, gave up.
Same with many US agencies giving excess fines to companies. etc. giving 100 million to rats? or whistle blowers. company pays the fine for their 'alledge' crimes and settle, SEC gets a cut of the 100 million.why should the rat get anything? SEC employees get half of any payment. that is how corrupt the SEC is now.
courts given these fines to people or companies. without thinking that the fines are excessive and unreasonable. and is considered state persecution when fines are too high. it's punitive and state persecution rather than preventative or fair fines. that amount that HSBC bank was force to pay close to 1.2 billion for 'alledged' money laundering is one special case. when entire exchange is money laundering and entire cryto coin industry is money laundering yet HSBC which is foreign bank main bussiness is in Asia is targeted either HSBC was competition in the lucrative forex business and cryto coin trading in the US market. HSBC just shut down all it branches in US after the 1.2 billion fine was paid.
The King of France owed huge debt to the knights of templars to fund wars and he could not pay so what he did, he killed the creditors by making false accusations of devil worshipping by the knight templars who are not the free masons.
Now with debts that are unreasonable and unjustified, the debtor can just kill the credistors as what the Germans did in war world 2. it was given unfair fines in the versailles treaty and debt carried interest so by 1930 due to high inflation the debt exploded, and no way Germany can repay the war debts or be 'enslaved' so it declared war on France and England. all because the debt given to Germany was excessive, unfair and unreasonable, the debt would have enslave the country if it was not written off after world war 2.
of the 44 million 'creditor claims'
a least 40 million is 'disputed' claims so this company only had 4 million in unpaid 'expenses' with 3 million in cash. in 2022.
why even pay a dime to some fake 40 million 'DISPUTED' claims. ?
it was easier and more expedient to just declare chapter 11 but was the plan to go bankrupt. and get sued and collect the 5 million insurance payout.
The Authorized Shares is 225M, and 119,080,135 of those shares are issued and Outstanding.
At one time, I think management was contemplating a 5:1 forward split. We may still see something like that. For example, maybe Taran will offer 5 shares of their stock, for every one share of HGEN stock, and end up with an OS of 595,400,675 shares. That OS was reported for us, at one time.
Any news will result in more than enough to pay off our Unsecured Creditors, and have this bankruptcy discharged. Remember, after TLD, I was able to sell shares at an average price of ~$28 (x 119,080,135 = a Market Cap of $3.3B, even without the spike of a recall of the loaned shares, or news regarding CMML).
We're dealing with the US government owning a sizable chunk of Moderna, and the ECB and German government heavily invested in Pfizer, plus these governments are providing the majority of the Regulatory Agencies' operating expenses, with government scientists also earning royalties from these companies.
So I agree that the best move is to look to Australia for the approval of lenz to treat CMML.
Management has more ice water in their veins than we do. I think it represents nothing less than stone cold resolve, and means that we will succeed.
and how the insurance company who paid out $5 million without a redflag? the employee of the insurance company which approves payout is probably bribed too. and insurance company gets ripped off. most of the time insurance company won't pay a dime and even hire private investigators for insurance fraud if it has red flags. and don't pay if there is suspicion of insurance fraud. especially for murders or death of life insurance where wife is murdered by husband and claims insurance, business insurance liability fraud is much easier to do insurance fraud. as nobody is murdered.
tough to get money when you owe 45 mm out the gate , so…
And for the $5 million dollar management insurance which was bough in 2022 and company filed a claim in 2023,, what insurance would not raise red flag that its insurance fraud. with some insurance companyagainst management lawsuits or management misconduct. it's just for legal fees or any fines the company has to pay for 'employee misconduct' the employees if they commit crimes are still personally liable for their 'crimes' if criminally responsible. and the money is paid to the company not the employee or any creditor claims.
management think they are buying insurance for murder or robbery. there is no insurance for robbery, if you found guilty of robbery or murder, the employee goes to jail. insurance is just to cover the cost of legal fees and fines in civil cases not criminal charges.
who sell that kind of insurance.
it's like the music companies buying insurance for their singers if the singer on contract dies, the music company gets paid $10 million insurance payment. the music company could have killed the singer and say it was suicide type of insurance fraud. like in korea, how can that many actors and singers just commit suicide. someone bought life 'business' insurance for them.
"Myelodysplastic syndrome (MDS) is a group of cancers that affect the bone marrow and blood. In MDS, immature blood cells in the bone marrow don't develop normally and instead die or become unhealthy. This can lead to a buildup of defective cells over time, which can cause problems like anemia, leukopenia, and thrombocytopenia."
https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/symptoms-causes/syc-20366977#:~:text=In%20a%20healthy%20person%2C%20bone,%2Dclotting%20platelets%20(thrombocytopenia).
I will not be surprised if lenzilumab is being used in the treatment of MDS in Mayo Clinic's Investigator Initiated Trial (IIT). And I think our CMO, Dr. Michael W Schuster, could be aiding Mayo in their IIT. This is his area of expertise.
https://doctors.stonybrookmedicine.edu/provider/Michael+W+Schuster/2250408
So with the low authorized shares 100M and low to no debt. Why didn't the company request additional shares and set up an offering to keep the company going instead of bankruptcy
Humanigen, Inc., paid off their loan from Hercules Capital, about $25M, as I recall, to prevent Hercules from gaining control of the IP, as the book value of the company plummeted.
ie ,if guilliani who was ordered by the court in civil court to owe 100 million bogus 'penalty' for defamation or any wrong doing and has only $1 million in assets and no way he can repay and cannot declare bankruptcy and have debts discharge all his income is theoretically garnished or can be taken so he is essentially a slave made by the 'state'. if there was no bankruptcy law as the 'debt' someone claims on his is beyond reasonable. and no way he can repay such debt but be slave. and debt can never be repaid.
Chapter 11 protects debtors from creditors to seize assets, harass debtor, after chapter 11, all creditors are not allowed to collect debts from hgenq. ..before chapter 11 debtors had right to force repayment and no way you can just declare bankruptcy and not repay. they even had debtor prisons. and how slavery came to be, debtors who could not repay loans were sold to slavery. and sold off to repay debts. many of the slaves who came to Africa to America were people who owed debts to invading armies and sold as slaves who could not repay debts.
Before chapter 11 bankruptcy law after the great depression was to preserve companies from dissolving and shutting down.
Bankruptcy court is mostly to determine if it is 'valid' bankruptcy to not repay debts.
you notice hgenq has NO bank loans as no bank would lend money to this company. the company like most startups if they need money can sell equity, as there is no need to get bank loan as most banks want collateral. or personal gaurantees on loans. because hgenq is a LLC, any debts incurred, owners of the company are not liable for it. even lawsuits against the individuals can only be criminal charges rather than business. if criminal conduct was involved but debts incurred by the company, etc owners of the corporation are not liable.
Thank you very much for providing that information, which did include Board of Director fees for Cheryl and all of the other Board members. But that is not the document I was looking for. I'll post it, when I see it again.
I don't think there is necessarily anything adversarial involved. I did, initially. But Kevin Xie probably coordinated the integration of lenz into the highly enhanced CAR-T platform used by Gracell, and I suspect they are paying license fees to us. I think the BOD resignations were scripted, and designed to disqualify us from NASDAQ. It was in the KBIO playbook.
The recall of my car, which has now been at the dealership for about a month, is going to cost me thousands to repair, and I need good financial news, not more of the same surprises I've been dealing with.
Docket 254 was sustained by Judge Shannon on May 21st in reference document 275 which can be seen here:
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1083368&projectCode=HUM&docketNumber=275&source=DM
I believe the document you are attempting to find is the debtors schedule/ statement of assets originally filed on January 31st and then amended on February 9th and entered as Docket #115 located here:
https://document.epiq11.com/document/getdocumentbycode?docId=4291480&projectCode=HUM&source=DM
It is important to note that document is filled out entirely by Henry Madrid and creditors mentioned may have no basis in fact other than to show the potential liabilities in order to move the Chapter 11 forward from the initial stages.
I have some speculation on why their names no longer appear, but I'd rather keep it to what I can truly see with my eyes.
Management's Objection regarding claims on account of Equity Interest was not what I had hoped it would be. Here is a list of the claimants, in this regard, in case you haven't seen it.
start on pg 19/26
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1079544&projectCode=HUM&docketNumber=254&source=DM
I mention it because I did not see Cheryl Buxton's name on it. But the list I saw did mention John Hohneker and Kevin Xie. Now, I see none of the three.
https://www.streetinsider.com/Board+Changes/Humanigen+%28HGEN%29+Announces+Resignations+of+Three+Directors%2C+Company+Now+not+Compliant+with+Nasdaq+Rules/21941128.html
Maybe I need SG44's eyes on this, or maybe I need to finish my first cup of coffee. But I think there has to be another version of the list somewhere.
I just find it a little curious. I still believe that we will have a successful conclusion by the time additional information relative to the co-exclusive licensing deal between Sanofi and Novavax is made known.
"...some non existent illegal hidden share scheme."
If a distribution is allowed to existing equity account holders, the identity of those holders will be determined "...(as reflected by DTC and/or the Debtor’s official register of holders of common stock)."
see Allowance, pg 52/85
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1089767&projectCode=HUM&docketNumber=309&source=DM
I was right to note the significance of the reported float of 192% of our Outstanding Shares, and to assume that total came from the Transfer Agent.
Even the latest version of our antagonist recognizes that there are more shares in our market, than issued by the company, if he thinks we have someone holding 110M shares, and there are another 36M shares out there somewhere.
those 110 million shares have control value. and decides who gets paid or have access to the companies bank accounts etc.
shares have no financial value other than control value. meaning the guy who owns the 110 million shares controls the chapter 11 filing process and still paying the 4 employees. the guy who still controls the company. even though the shares are technically 'worthless'
there is over 119 million shares outstanding
when the stock hit .04 cents and rugged was pulled over 100 million shares was sold between 1 cent and 4 cent..
now who bought all those millions of shares>
the ceo or management has the record of all the shareholders on record.
as for who owns the 110 million shares,, the ceo and CFO knows.
how you think dividends are paid to shareholders.
there is shareholder record of date and that info the company has it.
only 36 million of the shares are freely traded or registed to be traded
the 110 million share ownership is private information not disclosed publicly
you cannot buy all the shares of the company in the open market to have control of the company as only 36 million is publicly available to buy so no way anyone can buy all the shares in the open market or exchange to control the company or have any say in corporate matters. even if you own 36 million shares or all the freely traded shares, you still cannot have a seat in the board of directors or no say in the company.
and who owns 110 mm shares ?
delusion runs wild here
white collar crime like corporate embezzlement or political corruption is very hard to investigate or prosecute criminal charges without insider ratting or tips. normally the person just get fired from the job. rather than charged for 'embezzlement'. Today the corruption and embezzlement is in your face and getting more obvious and cannot be ignored like in mexico and country becomes failed state .
this entire trial is like watching a play....talking non-sense. with fake bankrupty filing
I'm in the process of reading today's Order issued by the bankruptcy court judge. Taking a break for dinner, so here is the link.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1089767&projectCode=HUM&docketNumber=309&source=DM
today zero volume
now one guy still owns 110 million shares and
still not sell his 110 million worth less shares?
this is what I call an illiquid market ZERO volume
not to mention dales insider trading, he should be behind bars to be frank. he benefited abnormally well for an insider
you can say management 'embezzled' corporate assets.
corporate embezzlement is grey area in white collar crime, the actions can be legal or illegal.
depending on the circumstance like pay 100x more than market value for services and products. or paying elon musk 56 billion in salary and say it was worth it. and he was paid fairly. and that board of directors approved it. when the ceo tells the board of directors what to do. or how to vote, it's called rigged vote. only one check box. like a shell game, you give three choices. or picks, all picks is same answer. the company is shell company that is now being dissolved and hgenq shares deregistered.either a new company is created and old shareholders may be getting new shares is how some corporate restructiuring occurs to avoid any legal issues.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43374
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |